Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Atezolizumab SC approval on slide 5.
September 15, 2024.
This is a Sunday. Does the FDA announce things on a Sunday?
Maybe Helen will make mention of Opdivo in tomorrows call??
From the call yesterday. First question. Helen is not sticking her neck out again by saying how many deals HALO will sign!!
Operator: [Operator Instructions] Your first question comes from the line of Jessica Fye with JPMorgan. Your line is open.
Jessica Phi: Hi, guys. Good afternoon. Thanks for taking my question. Just a couple here, I guess: first, what are your goals for signing new partnerships this year? And second, how quickly can you deploy the $750 million share repurchase authorization? Thank you.
Helen Torley: Thanks, Jess. I’ll take the first one. We certainly are off to a great start in 2024 with a robust set of meetings and forward momentum across all of our opportunities, that’s includes ENHANZE, the high volume auto-injector and the small-volume auto-injector. And our focus is on progressing all three of these types of deals. And we’re not putting a specific number on it, but we’re looking to advance all of these. And I look forward to updating you on that progress throughout the year. Nicole, will you tackle the question on the share repurchase new program?
January 11, 2024
From Sept 14, 2017
This is the way things use to happen. O, the good old days!!!!!
In its seventh and biggest deal to date, Halozyme partners with Bristol-Myers Squibb. Halozyme will get $105 million upfront for work on up to 11 targets for subcutaneous cancer drugs. This includes up to $1.76 billion in milestones, in addition to royalties for any drugs that reach the market.
Halozyme also expands an existing collaboration with Swiss drug giant Roche, adding $30 million upfront and $160 million in potential milestones for one new target for a subcutaneous drug.
On the HALO web site under careers they are looking for: V. P. Business Development and Specialty Account Manger. Not sure if these are new positions or if there were people in these positions that are no longer there for one reason or another.
Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV injection. The company was founded in 2008 and listed in KOSDAQ (196170.KQ).
Any more news from HALO before 12/31/2023 ?????
Roche buying Carmot Therapeutics for $2.7 billion plus up to $400 million as milestones. Carmot has an obesity drug injected subcutaneously once a week.
I have held HALO stock for many years. The last few posts about other companies developing SC is the most disturbing news I have ever considered. A one trick pony.
I thought the call was very good and the analysts seemed positive. Why is the stock price down?
Can anyone explain why this stock would go down after the call yesterday????? At one point in after hours HALO was up almost $4?????????????????
GREAT CALL!!
WHERE WILL IT BE BY THE END OF 2022?
Johnson & Johnson’s JNJ Janssen has won an arbitration against Genmab A/S GMAB on two matters related to their licensing pact for multiple myeloma drug Darzalex (daratumumab).
The first issue around daratumumab arose because Janssen announced a deal with Halozyme Therapeutics Inc (NASDAQ: HALO) to develop a subcutaneous formulation of daratumumab.
According to Janssen, Genmab must share in its royalty payments to Halozyme — representing a mid-single-digit percentage rate of sales — so Janssen could cut out its royalty payments to Genmab.
The three-person arbitration tribunal ruled that Janssen can continue to do that as an offset for its payment to Halozyme.
On the second issue, which concerns whether Janssen’s obligation to pay royalties to Genmab extends until Genmab-owned patents expire or until Janssen-owned patents expire, the tribunal determined that the line should be drawn at “the expiration or invalidation of the last-to-expire relevant Genmab-owned patent.”
Think it was about Halo Collective Inc.
Ms. Miyashita provided growth strategy and M&A transaction and integration consulting services to senior executives for businesses in the biotech, healthcare and technology industries. Prior to McKinsey, Ms. Miyashita served as Vice President, Corporate Development at IBM Corporation, an information technology company where she was involved in more than 100 acquisitions.
Let's see, Ms Miyashita involved in more than 100 acquisitions and HALO has a job posting for:
Associate Director, Corporate Development-Mergers Integration
R0000779 | San Diego | Posted 30+ Days Ago
Helen must be closing in on an acquisition?
Can someone explain why the company is out after more cash as per the 8K today? Are they getting ready to purchase another company?
Can someone explain why the company is out after more cash as per the 8K today? Are they getting ready to purchase another company?
Could it be that the General Counsel was actually "replaced" by someone with the skill set that could help take HALO to the next level?
Is anyone familiar with Xeris Pharmaceuticals. Helen mentioned the other day on the call when asked about competitors that maybe a device attached to a person to deliver drugs. Could this be a company Helen is looking to acquire?
Thanks for all the info about upcoming events. I read one post and I want to sell then I read another post and I want to buy more. Always appreciate everyone's ideas and input. I am going with buying more and cannot wait for biotech stocks to come back into favor.
In the call today Helen was more aggressive about pointing out ALL the possibilities coming into play in the future. She really laid out why 2027 is not going to be like stepping off a cliff for HALO. Revenue will continue to grow and will be extended out for many years.
She was not shy about pointing out the advantage of having over 500,000 people that have received the subcutaneous option and why a competitor would face an uphill climb trying to get into the market. Helen was at her best today!! If you have not watched the call it is well worth your time to do so.
Halozyme will have its day in the sun again when one or both of the following occur:
1) The momentum/meme stocks crash and retail participation starts to trend back to historical averages. This is when fundamentals will start to matter again. We have seen this movie before (late 90’a and early 2000’s).
2) Helen and team start sharing the halo/enhanze story with the retail cohort via social media, CNBC and Bloomberg. Helen might want to give interviews on YouTube with some of the young retail influencers or go back to MadMoney. Last time she went, the focus was on Pegph20. She now has a much more compelling story to share. Cramer will eat up the fantastic growth offered at PE of 13 and PEG of 0.7.
Smart/patient investors won’t mind if 1&2 don’t happen tomorrow. It just means they have more time to accumulate at these low prices.
[u]So glad to see HALO hit a new 52 week low and is now $20 off it's high and that we can accumulate more at these low prices??????????????
click on deepdj011, this person has posted the same three messages about a number of different stocks.????
Does anyone know if HALO is involved with the subcutaneous administration
of gantenerumab?
South San Francisco, CA -- October 8, 2021 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD).
Why will HALO be able to cancel existing agreements with companies not moving forward?
It is always exciting to hear about the opportunities where HALO is needed. Just wish one of the opportunities would come to fruition very soon.
biotechinvestor1 Tuesday, 05/11/21 05:45:08 PM
Re: maumar post# 6588 0
Post #
6589
of 6598
I on other hand love these gifts. Let’s revisit this day (5/11/21) in the future and see how big of a gift you said no to.
HALO - THE STOCK THAT KEEPS ON GIVING
41.93-0.75 (-1.76%)
As of 10:15AM EDT. Market open.
Halozyme hurt by downgrade after mixed Q1 results
Halozyme Therapeutics (NASDAQ:HALO) reported a mixed performance with its Q1 2021 financials on Monday after the close. The stock lost ~7.4% yesterday in reaction.
Piper Sandler has downgraded the stock to neutral from overweight, and the price target slashed to $48.00 from $50.00 per share implies a premium of ~12.5% to the previous close.
Noting his previous upgrade which was mostly based on an aggressive outlook for Darzalex Faspro’s early launch, Analyst Joseph Catanzaro says: “Our sense is that faspro’s impressive conversion trajectory has reached full appreciation.”
The subcutaneous formulation of multiple myeloma medication DARZALEX (daratumumab) is co-formulated with Halozyme's ENHANZE drug delivery technology, and it was granted FDA approval in May 2020.
In your post you had this is quotes meaning this is what Helen said:
“We will be making more new deals on Enhanze” Not mincing words.
I listened and re-listened to the call and never did Helen say the words you put in quotes.
At 27:52 in the presentation today Helen said " We will look to sign new collaborations"
not “We will be making more new deals on Enhanze” Not mincing words.
A stretch from "We will look" to "We will be making"
I am at the age where there might not be enough future for me to think I should be happy when the stock takes a big hit like this. I rather be happy looking at a PPS at an all time high!!
WHAT WILL HAPPEN WITH DIRECTOR KELLY WALKING OUT THE SATURDAY BEFORE THE WEEK OF THE EARNINGS CALL?
Someone mentioned they thought Roche may buy HALO. How would the March 1, 2021 issuing of the Convertible Senior Notes due 2027 affect a possible purchase by Roche or anyone else?
Announced what?
"It still can happen", but why would it happen?
Why would Roche pay HALO all the upfront fees to get at
something they already have.
Let's Take Another Look at Halozyme Therapeutics
HALO now looks like it can correct to the $34 to $30 area in the weeks ahead.
By BRUCE KAMICH Mar 04, 2021 | 12:05 PM EST REAL Money.
Bottom line strategy: I will assume that traders took profits on HALO on strength in the $48 to $55 area. HALO now looks like it can correct to the $34 to $30 area in the weeks ahead. Stand aside.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
Bottom line strategy: I will assume that traders took profits on HALO on strength in the $48 to $55 area. HALO now looks like it can correct to the $34 to $30 area in the weeks ahead. Stand aside.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.
I also send to "business development".
bd@halozyme.com
Wish HALO would get with Lilly on this!!
Bamlanivimab must be administered by intravenous (IV) infusion.
January 21 2021 - 08:27AM
Business Wire
Alert
Print
Share On Facebook
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).
Key details from the BLAZE-2 study are as follows:
Participants were grouped based on their COVID-19 status at baseline: 965 COVID-19 negative participants (299 residents and 666 staff) were in the prevention group, and 132 COVID-19 positive participants (41 residents and 91 staff) were in the treatment group;
Participants in each group were randomized to receive either 4,200 mg of bamlanivimab or placebo;
Serious adverse events were reported at a similar frequency in both placebo and bamlanivimab groups, consistent with previous safety observations in Phase 1 and Phase 2 trials;
Bamlanivimab reduced the risk of contracting COVID-19 by up to 80% in residents versus placebo (odds ratio 0.20; p=0.00026); and
All deaths attributed to COVID-19 occurred in residents receiving the placebo. There were no COVID-19-related deaths of participants receiving bamlanivimab.
“The data from the Phase 3 BLAZE-2 trial show that bamlanivimab provides effective protection against COVID-19 infection, with the greatest impact on the most vulnerable patients,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “Furthermore, data obtained from the treatment group are completely consistent with what was observed in the BLAZE-1 trial. This reinforces the importance of efforts to ensure high-risk patients get access to antibody therapy early in COVID-19 infection. We believe bamlanivimab can save lives if delivered early.”